This website does not function properly without javascript

Welcome to the Peeper lab website

The Peeper laboratory is in the brand-new Division of Molecular Oncology and Immunology at NKI. We develop and use function-based genomic approaches to better understand the mechanistic principles of cancer progression, and to identify novel therapeutic targets and predictive biomarkers for achieving more durable clinical responses for cancer patients. We have two main strategies. First, we want to increase our understanding of how cancer cells function and rewire their signaling networks. This will expose their weaknesses and allow or the identification of pharmacologically tractable vulnerabilities. Second, we are manipulating various cell types from the patient’s own immune system to enhance their specific cytotoxicity towards tumor cells. Also this approach should uncover new therapeutic targets, on immune cells. With these strategies, we aim to contribute to the development of combinatorial therapies, which simultaneously eliminate the patients’ tumor cells and harness their immune cells.


daniel



PI Daniel Peeper and Christian Blank (a clinician researcher) recently engaged in a partnership to complement our basic, translational and clinical fields of expertise. This warrants not only the clinical relevance of our research questions, but also facilitates translation of our laboratory findings (therapeutic targets, prognostic and predictive biomarkers) to the clinic, particularly by initiating trials that are run here at NKI.

News & highlights


  • vacancies(September 2017) Kongs study on cancer drug addiction was published in Nature
  • vacanciesWe currently have job openings for a PhD student ("phenotype switching") and a PhD Student / Postdoc ("combination targeted- and immuno-therapies"). For more info, click here or here.
  • vacancies(June 2016) Kristel and Oscar uncover a new BRAF kinase duplication mutant rendering melanomas resistant to vemurafenib in Cell reports
  • vacancies(2016) Daniel was elected to the Academia Europaea
  • vacanciesWe currently have job openings for a PhD student ("phenotype switching") and a PhD Student / Postdoc ("combination targeted- and immuno-therapies"). For more info, click here or here.
  • vacancies(November 2015) Daniel Peeper receives Outstanding Research Award from the Society of Melanoma Research
  • kemper2(June 2015) Kristels study on intra- and inter-tumor heterogeneity in patient-derived xenografts of melanoma has been published in EMBO Molecular Medicine
  • vacanciesWe currently have job openings for a PhD student ("phenotype switching") and a PhD Student / Postdoc ("combination targeted- and immuno-therapies"). For more info, click here or here.
  • kuilman6(February 2015) Thomas' and Oscar's study on the use of off-target reads for copy number detection has been published in Genome Biology
  • mueller(December 2014) Judith's study on the effect of the MITF/AXL ratio on targeted drug sensitivity in melanoma has been published in Nature Communications
  • vacanciesWe currently have job openings for a PhD student ("phenotype switching") and a PhD Student / Postdoc ("combination targeted- and immuno-therapies"). For more info, click here or here.
  • smit3(November 2014) Patricia's study on synthetic lethality between hypoxia and DNA damage response inhibition has been published in Cell Reports
  • kaplon(May 2013) Joanna's study on OIS, metabolism and melanoma therapy published in Nature with a preview in Cell and a research watch in Cancer Discovery.
  • vacanciesWe currently have job openings for a PhD student ("phenotype switching") and a PhD Student / Postdoc ("combination targeted- and immuno-therapies"). For more info, click here or here.
  • ERCsynergy(2013) Daniel Peeper, together with five other researchers, has received a 15M€ ERC Synergy grant.



logo